Interferon gamma inhalation - RELIEF THERAPEUTICS Holding

Drug Profile

Interferon gamma inhalation - RELIEF THERAPEUTICS Holding

Latest Information Update: 22 Sep 2016

Price : $50

At a glance

  • Originator mondoBIOTECH
  • Developer RELIEF THERAPEUTICS Holding
  • Class Antineoplastics; Interferons; Lymphokines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity No
  • Available For Licensing Yes - Idiopathic pulmonary fibrosis

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis

Most Recent Events

  • 19 Sep 2016 Interferon gamma inhalation is available for licensing in USA, Europe as of 19 Sep 2016.
  • 19 Sep 2016 Phase-II clinical trials in Idiopathic pulmonary fibrosis (Inhalation)
  • 19 Sep 2016 Interferon gamma inhalation - RELIEF THERAPEUTICS receives Orphan Drug status for Idiopathic pulmonary fibrosis in European Union before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top